 |
 |

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—Reply
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In Reply: Drs FitzGerald, Patrono, and Hawkey write that review papers they authored were inappropriately included in the Table in our article, explaining that their articles were independently authored without discussion of their content with Merck before publication. The Table, as stated in its legend and in the text of the article, includes articles identified from internal documents,1-2 as well as other articles by investigators identified within internal documents. Articles by such investigators were found by searching MEDLINE, as we described. All of these articles were examined to better understand patterns of disclosure, as we believed that either their mention within internal documents or the mention of specific investigators suggested that Merck was aware of the publication and perhaps had provided support for the project. Correspondence with Merck, acknowledged by FitzGerald and Patrono, led to the identification of their articles using MEDLINE. To our knowledge, these articles were not discussed . . . [Full Text of this Article]
Joseph S. Ross, MD, MHS
joseph.ross@mssm.edu Department of Geriatrics and Adult Development Mount Sinai School of Medicine New York, New York
David S. Egilman, MD, MPH
Department of Community Health Brown University School of Medicine Providence, Rhode Island
Harlan M. Krumholz, MD, SM
Department of Medicine Yale University School of Medicine New Haven, Connecticut
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED LETTERS
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():900-900.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():900-901.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():901-901.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():901-901.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
, , and
JAMA. ;300():901-902.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():902-902.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():902-903.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():903-903.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():903-904.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():904-904.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
and
JAMA. ;300():904-904.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
and
JAMA. ;300():905-906.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals
Hirsch
Mayo Clin Proc. 2009;84:811-821.
FULL TEXT
|